PharmaCyte appoints Robert Weinstein to Board, removes cumulative voting

PharmaCyte Biotech, Inc.

Robert Weinstein appointed to Board on Nov 14, 2022; chairs Audit Committee and will join Nominating Committee if elected at Dec 28, 2022 annual meeting.
Interim CEO Joshua Silverman's month-to-month employment formalized; monthly salary set at $31,250.
Bylaw amended to eliminate cumulative voting for directors; elections now decided by plurality vote.
Board expanded from five to six members effective immediately.

item 5.02 item 5.03 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Robert Weinstein

Director

PMCB · PharmaCyte Biotech, Inc.

Effective: 2022-11-14
Filed: November 18, 2022, 6:59 PM ET

On November 14, 2022, the board of directors (the “Board”) of PharmaCyte Biotech, Inc. (the “Company”) increased the size of the Board to six members and appointed Robert Weinstein to serve as a member of the Board, effective immediately.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Robert Weinstein was appointed as Director at PharmaCyte Biotech, Inc..

Action: appointed
Role: Director

Exact text from the filing

On November 14, 2022, the board of directors (the “Board”) of PharmaCyte Biotech, Inc. (the “Company”) increased the size of the Board to six members and appointed Robert Weinstein to serve as a member of the Board, effective immediately.

View on SEC.gov

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

PharmaCyte Biotech, Inc.: Removed cumulative voting provision for director elections and replaced with plurality voting (effective 2022-11-14).

Change: bylaw amendment
Effective: 2022-11-14

Exact text from the filing

On November 14, 2022, the Board approved an amendment (the “Bylaw Amendment”) to the Company’s bylaws, as amended (the “Bylaws”), effective immediately. Pursuant to the Bylaw Amendment, the provision of the Bylaws allowing for cumulative voting in connection with the election of directors, which was invalid in the Bylaws, was removed and replaced with a provision allowing for the election of directors only by means of a plurality.

View on SEC.gov

42 governance changes filed in the last 30 days. Browse all governance changes →

PharmaCyte Biotech, Inc. filing history →

Source: SEC EDGAR

accession 0001683168-22-007894

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.